Entrada Therapeutics Expects Four DMD Clinical Programs by 2026

Entrada Therapeutics reported progress across its robust development portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases. Clinical-Stage Development Pipeline: Entrada continues to advance multiple clinical programs in people living with Duchenne muscular dystrophy in the U.K., EU and U.S. In 2026, the Company expects to have four clinical-stage programs in its DMD franchise. ELEVATE-44-201: The Company completed dosing of Cohort 1 of the global Phase 1/2 multiple ascending dose portion of the clinical study of ENTR-601-44 in ambulatory patients living with DMD who are amenable to exon 44 skipping, and transitioned to the open label, Phase 2 portion of the study. ELEVATE-44-102: The Company expects to initiate a Phase 1b MAD clinical study of ENTR-601-44 in ambulatory and non-ambulatory adults living with DMD in the U.S. in the first half of 2026. ELEVATE-45-201: The Company initiated patient dosing in the global Phase 1/2 MAD portion of the clinical study of ENTR-601-45 in ambulatory patients living with DMD who are amenable to exon 45 skipping. ELEVATE-50-201: The Company received regulatory authorization from the U.K.'s Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to initiate a Phase 1/2 MAD clinical study of ENTR-601-50. ENTR-601-51: The Company expects to submit global regulatory applications for ENTR-601-51 in 2026. VX-670: Vertexcontinues to enroll and dose the MAD portion of the global Phase 1/2 clinical trial of VX-670 in people living with DM1, which will assess both safety and efficacy. Vertex is on track to complete enrollment and dosing in the trial in the first half of 2026.